Resistell Antibiotic Susceptibility Test

World's fastest phenotypic Antibiotic Susceptibility Test

Resistell’s rapid AST is growth independent. It reduces time to result from days to a few hours. It enables targeted use of antibiotics from day one.

Technology:
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Infection prevention
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

Microorganisms:
  • Bacteria
  • Fungi
  • Yeasts
  • Viruses
  • Parasites

Application:
  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Validation
  • Market entry
  • Research
  • Development
  • Marketed product

Organization:
  • Company
  • Academia
  • Institute
  • NGO
  • Government

Partnering:
  • License
  • Co-develop
  • Joint Venture
  • Sell
  • Outsource

Funding organisation:
  • OTHER / NA
  • CARB-X
  • FIND
  • GARDP
  • REPAIR

Infectious disease area:
  • UTI
  • STI
  • BSI
  • RTI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia
  • North America
  • South America
  • Africa
  • Oceania


– technological know-how
– established position on diagnostic and/or R&D market
– distribution channels
– interest to further develop technology
– interest in new clinical indications

Resistell is a startup developing nanomotion technology platform for phenotypic Antimicrobial Susceptibility Testing and analysis of cell metabolism.

Resistell’s nanomotion based AST is under development for multiple indications, including blood stream infections, UTI, TB, Chlamydia and many other. In addition we offer our technology for research on cells’ metabolism.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed